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Rickettsia prowazekii, a parasitic Gram-negative bacterium, is in the second-
highest biodefense category of pathogens of the National Institute of Allergy
and Infectious Diseases, but only a handful of structures have been deposited
in the PDB for this bacterium; to date, all of these have been solved by the
SSGCID. Owing to its small genome (about 800 protein-coding genes), it relies
on the host for many basic biosynthetic processes, hindering the identiﬁcation
of potential antipathogenic drug targets. However, like many bacteria and
plants, its metabolism does depend upon the type II fatty-acid synthesis (FAS)
pathway for lipogenesis, whereas the predominant form of fatty-acid biosynth-
esis in humans is via the type I pathway. Here, the structure of the third enzyme
in the FAS pathway, 3-ketoacyl-(acyl-carrier-protein) reductase, is reported at a
resolution of 2.25 A ˚ . Its fold is highly similar to those of the existing structures
from some well characterized pathogens, such as Mycobacterium tuberculosis
and Burkholderia pseudomallei, but differs signiﬁcantly from the analogous
mammalian structure. Hence, drugs known to target the enzymes of pathogenic
bacteria may serve as potential leads against Rickettsia, which is responsible for
spotted fever and typhus and is found throughout the world.
1. Introduction
Epidemic typhus has afﬂicted humans for a long time, with the ﬁrst
written record going back to 1083 AD (Szybalski, 1999). The obligate
bacterial parasite Rickettsia prowazekii is responsible for the disease,
which is transmitted by various arthropod vectors, most commonly
body lice (Pediculus humanus humanus) or ﬂying squirrel ﬂeas
(Orchopeashowardii)andlice (Neohematopinus sciuropteri),through
their saliva or feces. Epidemic typhus ﬂourishes in areas with over-
crowding or poor hygiene, such as jails or refugee camps. Although
louse control has succeeded in suppressing typhus in the modern era,
recent outbreaks in the USA (Reynolds et al., 2003), Africa (Mokrani
et al., 2004) and Europe (Tarasevich et al., 1998) have re-established
R. prowazekii as a re-emerging disease threat; its potential use in
bioterrorism (Radulovic & Azad, 2002) places it in category B of the
Biodefense Category A, B and C Priority Pathogens of the National
Institute of Allergy and Infectious Diseases.
The genome of R. prowazekii, a member of the Gram-negative
alphaproteobacteria, is not large at just over 1.1 million base pairs,
with only 834 open reading frames found (Andersson et al., 1998).
This reduced proteome is representative of the dependence of
Rickettsia on its host for many biosynthetic functions and leaves
fewer innate enzyme targets for antipathogenic targeting. One well
conserved pathway that it shares with other bacterial pathogens is for
fatty-acid biosynthesis as a primary source of cell-membrane lipids.
In R. prowazekii fatty-acid biosynthesis occurs via the type II fatty-
acid synthase pathway, which is thought to be descendant from an
algal plastid (Wilson, 2002) and consists of four to eight individual
enzymes that start with acetyl coenzyme A and malonyl-(acyl-carrier-
protein) to create elongated fatty acids for the lipid bilayer (Fig. 1). In
contrast, human fatty-acid biosynthesis is performed by a single large
multifunctional peptide, the multienzyme type I fatty-acid synthase,
which passes the substrate from one domain to the next. 3-Ketoacyl-(acyl-carrier-protein) [3-ketoacyl-(ACP)] reductase, gene name fabG,
is the third enzyme in the type II pathway and catalyzes the chemical
reaction
ð3RÞ-3-hydroxyacyl-ðacyl-carrier-proteinÞþNADP
þ  !
3-oxoacyl-ðacyl-carrier-proteinÞþNADH þ H
þ:
While many structures of 3-ketoacyl-(ACP) reductase have been
solved, those from Escherichia coli (Price et al., 2001), Mycobacterium
tuberculosis (Cohen-Gonsaud et al., 2002) and Burkholderia pseudo-
mallei (PDB entry 3ftp; Seattle Structural Genomics Center for
Infectious Disease, unpublished work) to name only a few, only ﬁve
structures in total have been solved for Rickettsia and the solution of
the structure of an essential pathway enzyme in this bacterial parasite
holds promise for drug development against typhus.
2. Methods
2.1. Protein expression and purification
FabG from R. prowazekii strain Madrid E (NCBI NP_221114;
fabG gene RP762; UniProt P50941; Pfam ID PF00106; EC 1.1.1.100)
spanning the full-length protein from residues 1 to 241 was cloned
from genomic DNA into a pAVA0421 vector using ligation-
independent cloning (Aslanidis & de Jong, 1990) to produce a
construct with an uncleaved N-terminal hexahistidine-afﬁnity tag
followed by the human rhinovirus 3C protease-cleavage sequence
(sequence MAHHHHHHMGTLEAQTQGPGS-ORF). R. prowa-
zekii FabG was expressed in E. coli using BL21(DE3)R3 Rosetta cells
and autoinduction medium in a LEX bioreactor as follows. A 3 ml
starter culture of LB broth with ampicillin was grown for  18 h at
310 K. ZYP-5052 auto-induction medium was freshly prepared as per
Studier’s published protocols (Studier, 2005). Ampicillin was added
to 2 l sterile auto-induction medium, which was inoculated with all of
the overnight culture and then placed into the LEX bioreactor. The
culture was grown for  24 h at 298 K; the temperature was reduced
to 288 K and the culture was grown for a further  60 h. To harvest,
the cultured medium was centrifuged at 4000g for 20 min at 277 K.
The cell paste was ﬂash-frozen in liquid nitrogen and stored at 193 K.
The frozen cells were resuspended in lysis buffer (25 mM HEPES
pH 7.0, 500 mM NaCl, 5% glycerol, 30 mM imidazole, 0.025% sodium
azide,0.5%CHAPS, 10 mMMgCl2,1mMTCEP, 250 ng ml
 1AEBSF
and0.05 mgm l
 1lysozyme).Theresuspended cellpelletwasdisrupted
on ice for 30 min with a Virtis sonicator (408912; set at 100 W power
with alternating cycles of 15 s pulse on and 15 s pulse off). The cell
debris was incubated with 20 ml Benzonase nuclease (EMD Chemi-
cals; 25 units ml
 1) at room temperature for 45 min and clariﬁed by
centrifugation on a Sorvall SLA-1500 at 14 000 rev min
 1 for 75 min
at 277 K. The protein was puriﬁed from the clariﬁed cell lysate by
immobilized metal-afﬁnity chromatography on an Ni–NTA HisTrap
FF 5 ml column (GE Healthcare) equilibrated with binding buffer
(25 mM HEPES pH 7.0, 0.5 M NaCl, 5% glycerol, 30 mM imidazole,
0.025% sodium azide, 1 mM TCEP) at 277 K. The recombinant
protein was eluted with 250 mM imidazole. The protein was collected
in the ﬂowthrough and was further resolved by size-exclusion chro-
matography (SEC) using a HiLoad 26/60 Superdex 200 column (GE
Healthcare) at 277 K. Pure fractions collected in SEC buffer (25 mM
HEPES pH 7.0, 500 mM NaCl, 2 mM DTT, 0.025% sodium azide
and 5% glycerol) as a single peak were pooled and the protein
was concentrated to 25.35 mg ml
 1, as determined via A280 including
compensation for the absorption coefﬁcient, with good solubility.
The 2.5 ml sample was ﬂash-frozen and stored at 193 K prior to
crystallography.
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Figure 1
Fatty-acid biosynthetic pathway for R. prowazekii.T h eR. prowazekii fatty-acid biosynthesis map from the KEGG PATHWAY database (Kanehisa & Goto, 2000) is shown
with FabG highlighted in red.2.2. Crystallization and X-ray data collection
For the FabG target at a protein concentration of 23.4 mg ml
 1 in
SEC buffer, two sparse-matrix screens were set up, JCSG+ (Emerald
BioSystems) and PACT (Molecular Dimensions), following the
strategy of Newman et al. (2005). 0.4 ml protein solution was mixed
with 0.4 ml well solution and equilibrated at 289 K against 100 ml
reservoir solution using 96-well Compact Jr crystallization plates
from Emerald BioSystems. Crystals suitable for diffraction studies
were obtained within two weeks from JCSG+ screen condition D3:
100 mM sodium/potassium phosphate pH 6.2, 50% PEG 200, 200 mM
NaCl. The crystals, which were approximately 0.1–0.15 mm in each
direction, did not need additional cryoprotection and were ﬂash-
frozen by plunging them into liquid nitrogen.
A native data set was collected to 2.25 A ˚ resolution in-house at
Cu K  wavelength using a Rigaku SuperBright FR-E+ rotating-
anode X-ray generator equipped with Osmic VariMax HF optics and
a Saturn 944+ CCD detector (Table 1). Because of the rather long c
axis (183 A ˚ ) and the rather small in-house detector (94.4 mm), the
data set was collected with ﬁne ’ slicing (0.3 ). The diffraction data
were reduced with XDS/XSCALE (Kabsch, 2010) to 2.25 A ˚ resolu-
tion. The crystals belonged to the primitive tetragonal space group
P41212. The data-collection and reﬁnement statistics are summarized
in Tables 1 and 2.
2.3. Structure solution and refinement
Using the BLAST (Altschul et al., 1997) homology-search server
at NCBI, Brucella melitensis glucose/ribitol dehydrogenase (PDB
entry 3emk; Seattle Structural Genomics Center for Infectious
Disease, unpublished work) was found to be the closest homolog with
a known structure at the time, with 54% sequence identity. The
monomer of PDB entry 3emk was modiﬁed with the CCP4 program
structural communications
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Table 1
Data-collection statistics.
Values in parentheses are for the highest resolution shell.
Space group P41212
Unit-cell parameters (A ˚ ) a = b = 74.16, c = 183.01
Wavelength (A ˚ ) 1.5418
Resolution range (A ˚ ) 50–2.25 (2.31–2.25)
No. of unique reﬂections 24572 (1687)
Multiplicity 5.9 (2.3)
Completeness (%) 97.9 (93.0)
Rmerge† 0.056 (0.375)
Mean I/ (I) 20.7 (2.3)
† Rmerge =
P
h
P
i jIiðhÞ h IðhÞij=
P
h
P
i IiðhÞ.
Table 2
Reﬁnement and model statistics.
Resolution range (A ˚ ) 50–2.25
Rcryst† 0.213
Rfree† 0.274
No. of reﬂections 24573
Completeness (%) 98.1
No. of reﬂections, test set 1256
Completeness, test set (%) 5.1
R.m.s.d. bonds (A ˚ ) 0.017
R.m.s.d. angles ( ) 1.60
Protein atoms 3252
Nonprotein atoms 129
Mean B factor (A ˚ 2) 38.8
Residues in favored region 419 (96.3%)
Residues in allowed region 13 (3.0%)
Residues in disallowed region 3 (0.7%)
MolProbity score (percentile) 2.34 (67th)
PDB code 3f9i
† Rfree =
P
hkl
   jFobsj j Fcalcj
   =
P
hkl jFobsj. The free R factor was calculated using 5% of
the reﬂections omitted from the reﬁnement (Winn et al., 2011).
Figure 2
Crystal structure of R. prowazekii 3-ketoacyl-(ACP) reductase (FabG). FabG from
R. prowazekii crystallizes with two molecules per asymmetric unit, which are shown
as ribbon diagrams with purple helices and yellow strands. The active-site residues
(Ser143, Tyr156 and Arg160) are grouped near the loop connecting  5 and  5.
Secondary-structure elements are labeled from both chains. A tetramer is
generated by crystallographic symmetry. Molecules A0 and B0 are shown as ribbon
diagrams with blue helices and yellow strands. The ﬁgure was generated with
CCP4mg (McNicholas et al., 2011).
Figure 3
Structural superimpositions of monomeric units for FabG. In this ﬁgure, the
monomers of FabG from R. prowazekii (PDB entry 3f9i; purple helices, yellow
strands), from E. coli (PDB entry 1i01; magenta), from M. tuberculosis (PDB entry
1uzm; light blue) and the NADP
+-bound structure from V. cholerae (PDB entry
3rsk, pink) are superimposed. There is a signiﬁcant structural variability between
these structures in the proximity of the NADP
+-binding site.CHAINSAW (Stein, 2008; Winn et al., 2011), which deleted four
residues (Glu77–Gly80) and mutated 107 residues to their last
common atom. Based on a packing density VM (Matthews, 1968) of
2.24 A ˚ 3 Da
 1, corresponding to 45% solvent, two molecules were
expected to be present in the asymmetric unit. Molecular replace-
ment was performed with the CCP4 program Phaser (McCoy et al.,
2007) using the modiﬁed model of 3emk and data to 3 A ˚ resolution.
Phaser could position two molecules in the asymmetric unit with
rotation/translation Z scores of 5.4/17.7 and 5.4/26.7, respectively, and
an R factor of 0.52. The initial model was improved with ARP/wARP
(Langer et al., 2008), which built 367 residues in 13 chains with
Rwork = 0.259 and Rfree = 0.307. This model was then extended and
reﬁned in iterative cycles of REFMAC5 (Murshudov et al., 1997) and
Coot (Emsley et al., 2010). In REFMAC5 no data-cutoff criteria were
used and NCS restraints were applied given the limited resolution of
the data.
The ﬁnal model for FabG contained two protein chains spanning
residues Met1–Val241 for either chain, with gaps at Gly85–Asp99,
Gly138–Gly141 and Lys182–Leu189 in chain A and Thr87–Asp99 and
Ile139–Gly141 in chain B. The two protomers are very similar and
superimposed with an r.m.s.d. of 0.44 A ˚ . 129 water molecules were
located. In reﬁning this structure the inclusion of TLS terms did not
signiﬁcantly improve the reﬁnement; hence, no anisotropic
displacement factors were deposited. The ﬁnal structure was vali-
dated with Coot and MolProbity (Chen et al., 2010) and deposited in
the PDB with the identiﬁer 3f9i.
3. Results and discussion
3.1. Overall structure
The structure of R. prowazekii FabG (Fig.2) is very similar to those
reported for E. coli FabG and other bacterial FabGs; the protomer
assumes a Rossmann-fold structure with a seven  -stranded twisted
parallel  -sheet ﬂanked by four  -helices on either side and two
      motifs at the core (Fig. 2). R. prowazekii FabG crystallizes
with two protomers per asymmetric unit. A tetramer is generated by
crystallographic symmetry. According to PISA analysis (Krissinel &
Henrick, 1997) there are two types of interface: a larger interface
exists between AB and A0B0 comprising 1690 A ˚ 2 with an estimated
binding energy of  126 kJ mol
 1 and a smaller interface exists
between AB0 and A0B comprising 845 A ˚ 2 with an estimated binding
energy of  71 kJ mol
 1. For FabGs tetramers are typically observed.
It is therefore assumed that R. prowazekii FabG is in a tetrameric
state.
3.2. Comparison with other bacterial 3-ketoacyl-(ACP) reductases
The R. prowazekii FabG shows 1.33 A ˚ r.m.s.d. with the E. coli
structure (PBD entry 1i01; Price et al., 2001) over 205 residues, 1.26 A ˚
r.m.s.d. with the M. tuberculosis structure (PDB entry 1uzm; Cohen-
Gonsaud et al., 2002) over 201 residues and 1.22 A ˚ r.m.s.d. with the
NADP
+-bound Vibrio cholerae structure (PDB entry 3rsh; J. Hou,
M. Chruszcz, D. Cooper, M. Grabowski, H. Zheng, T. Osinski,
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Figure 4
Alignment of solved structures of bacterial 3-ketoacyl-(ACP) reductases. Multiple sequence and secondary-structure alignment of bacterial orthologs. Numbering along the
top is based on the alignment consensus. Predicted  -helices,  -strands, coils and turns are shown as pink cylinders, yellow arrows, grey corkscrews and blue curved arrows,
respectively. Sequences are taken from the PDB. From top to bottom: E. coli, 1i01 (Price et al., 2001); M. tuberculosis, 1uzm (Cohen-Gonsaud et al., 2002); Pseudomonas
aeruginosa, 2b4q (Miller et al., 2006); Aquifex aeolicus, 2pnf (Q. Mao, R. Huether, W. L. Duax & T. C. Umland, unpublished work); R. prowazekii, 3f9i (this work);
Burkholderia pseudomallei, 3ftp (Seattle Structural Genomics Center for Infectious Disease, unpublished work); Bartonella henselae, 3grp (B. L. Staker, unpublished work);
Brucella melitensis, 3n74 (Seattle Structural Genomics Center for Infectious Disease, unpublished work). This ﬁgure was prepared with Geneious (Drummond et al., 2010).I. Shumilin, W. Anderson & W. Minor, unpublished work) over 208
residues, as shown in Fig. 3, whereas the r.m.s.d. with Sus scrofa
mammalian FAS (PDB entry 2vz8; Maier et al., 2008), used here as a
homologue for the unsolved human FAS structure, is 2.5 A ˚ over 80%.
Although there are closer orthologs to Rickettsia FabG than the three
aforementioned bacterial structures, these four structures represent
prominent bacterial pathogens and the overall structural similarity is
useful to note. Furthermore, a multiple sequence alignment (Fig. 4) of
eight bacterial orthologs of 3-ketoacyl-(ACP) reductase ranges from
30 to 54% sequence identity over 93–95% sequence coverage. Of
these eight orthologs, only one is not an NIAID Class A–C pathogen.
Based on these high overall correspondences in sequence and
secondary and tertiary structure, conclusions drawn from the other
bacterial structures may also be applicable to the Rickettsia protein.
FabG has been shown to have negative cooperative binding of
NADPH (Price et al., 2001) and this effect is enhanced by the
presence of acyl carrier protein (ACP). NADPH binding also
increases the afﬁnity and decreases the maximum binding of ACP to
FabG. Thus, unlike other members of the short-chain dehydrogenase/
reductase superfamily, FabG undergoes a substantial conformational
change upon cofactor binding that organizes the active-site triad
(Ser143, Tyr156 and Arg160) and alters the afﬁnity of the other
substrate-binding sites in the tetrameric enzyme (Price et al., 2001).
This behavior could explain why the pocket around the NADP
+ in
Fig. 3 differs signiﬁcantly among the four bacterial targets and serves
as a caveat that a given bacterial FabG antidote may not immediately
be effective against Rickettsia.
While a number of antimicrobial options have been identiﬁed for
targeting most of the enzymes in the FAS II pathway, FabG is still
relatively unaddressed, in part owing to the conformational change
that it undergoes. Epigallocatechin gallate (EGCG), along with other
related plant polyphenols, has been shown to be a mixed-type inhi-
bitor of E. coli FabG, although inhibiting fatty-acid synthesis was not
the only target of EGCG (Zhang & Rock, 2004). Similar ﬁndings
have been generated against the eukaryotic Plasmodium falciparum
ortholog (Tasdemir et al., 2006). Additionally, plant polyphenols have
not been considered to be effective against Gram-negative bacteria
owing to their effective permeability barrier as well as the action of
efﬂux pumps; deactivating these pumps in conjunction with plant
polyphenol administration has been shown to be effective (Tegos et
al., 2002). Nonetheless, Zhang and coworkers concluded that the
ﬂexible substrate-binding pocket, while a challenge to model for
druggability (Price et al., 2004), offers the prospect of utilizing a more
potent slow-binding inhibitor (Zhang et al., 2006). In contrast,
Poncet-Montange and coworkers inferred from an inactivated mutant
form of the M. tuberculosis FabG1 that drug-target screening could
be among ligands that freeze the enzyme in its inactive form (Poncet-
Montange et al., 2007).
4. Conclusion
The SSGCID has solved a 2.25 A ˚ resolution structure of R. prowa-
zekii FabG, a 3-ketoacyl-(acyl-carrier-protein) reductase, which
corresponds well to the solved structures for other notable bacterial
pathogens while differing from mammalian analogs. For Rickettsia
in particular this is a signiﬁcant target for drug development as the
organism has a minimal proteome with very few essential biosyn-
thetic pathways maintained. Owing to a signiﬁcant conformational
change during substrate binding, it has been difﬁcult to identify
suitable inhibitors for this essential and highly conserved enzyme.
The authors wish to thank the entire SSGCID team. This research
was funded under Federal Contract No. HHSN272200700057C from
the National Institute of Allergy and Infectious Diseases, National
Institutes of Health, Department of Health and Human Services.
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